Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome

Annals of Hematology

Volumn 80, Issue 1, 2001, Pages 53-57

  Yilmaz, A ^a   Kaufmann, C C ^a   Binder, C ^a   Wormann B ^b   Haase, D ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

Amifostine; Antiapoptotic therapy; Cytogenetics; Myelodysplastic syndome; Secondary AML

Indexed keywords

AMIFOSTINE; AMINOTHIOL; ANTIEMETIC AGENT; CIPROFLOXACIN; CYTOKINE; DEXAMETHASONE; DNA; ETOPOSIDE; GLUTATHIONE; HEMOGLOBIN; HLA ANTIGEN; HYDROXYUREA; IDARUBICIN; OXYGEN RADICAL; PYRIMIDINE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CASE REPORT; CELL STRUCTURE; CHROMOSOME 11Q; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EPISTAXIS; ERYTHROBLAST; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HEMATOPOIESIS; HOSPITALIZATION; HUMAN; INFECTION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAINTENANCE THERAPY; MALE; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY ANEMIA; STRUCTURE ANALYSIS; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

AMIFOSTINE; APOPTOSIS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RADIATION-PROTECTIVE AGENTS;

EID: 0035131406     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770000224     Document Type: Article

References (28)

1. Proposals for the classification of the myelodysplastic syndromes
2. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML cooperative group
3. Clinical status and optimal use of amifostine
4. Treatment of myelodysplastic syndrome (MDS) with amifostine
5. Treatment of myelodysplastic syndrome (MDS) with amifostine
6. International scoring system for evaluating prognosis in myelodysplastic syndromes
7. Cytogenetic findings in 179 patients with myelodysplastic syndromes
8. Cytogenetic analysis of CD34 + subpopulations in AML and MDS characterized by the expression of CD38 and CD117
9. Prognostic relevance of cytogenetic subgroups in 357 patients with myelodysplastic syndromes
10. An international system for human cytogenetic nomenclature
11. The use of an oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukemia in the elderly: A report of toxicity and efficacy
12. Treatment of myelodysplastic syndrome (MDS) with amifostine (AMF)
13. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow
14. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
15. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia
16. The role of apoptosis, proliferation and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS
17. Oxidative DNA damage in CD34 + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration
18. Effective treatment of poor prognosis AML
19. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
20. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
21. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastic reveals extensive apoptosis as the probable basis for ineffective hematopoiesis
22. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines
23. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: The cause-effect relationship
24. Hematopoietic and cytogenetic responses to novel anti-cytokine therapy in myelodysplastic syndromes (MDS)
25. Cytopenias improve in response to amifostine pentoxifylline/ciprofloxacin/dexamethason (PCD) in patients with myelodysplastic syndromes (MDS)
26. Measurement of apoptosis, prolifertation and three cytokines in 46 patients with myelodysplastic syndromes
27. Apoptosis in patients with myelodysplastic syndromes: Differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes
28. Successful treatment of myelodysplastic syndrome with amifostine